Nelfinavir
( DrugBank: Nelfinavir / KEGG DRUG: Nelfinavir mesylate, Nelfinavir )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 49 | Systemic lupus erythematosus | 1 |
| 265 | Lipodystrophy | 4 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 331 | Idiopathic multicentric castleman disease | 1 |
49. Systemic lupus erythematosus
Clinical trials : 1,414 / Drugs : 1,077 - (DrugBank : 181) / Drug target genes : 130 - Drug target pathways : 209
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
265. Lipodystrophy
Clinical trials : 133 / Drugs : 176 - (DrugBank : 58) / Drug target genes : 30 - Drug target pathways : 102
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
331. Idiopathic multicentric castleman disease
Clinical trials : 44 / Drugs : 58 - (DrugBank : 32) / Drug target genes : 43 - Drug target pathways : 168
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|